The role of JAK2 abnormalities in hematologic neoplasms.

In 2005, an activating mutation in the Janus kinase 2 (JAK2) was identified in a significant proportion of patients with myeloproliferative neoplasms, mainly polycythemia vera, essential thrombocythemia and primary myelofibrosis. Many types of mutations in the JAK-STAT pathway have been identified,...

Full description

Bibliographic Details
Main Author: Mohammed Khalid Alabdulaali
Format: Article
Language:English
Published: PAGEPress Publications 2009-07-01
Series:Hematology Reports
Subjects:
Online Access:http://www.pagepress.org/journals/index.php/hr/article/view/176
id doaj-8a4df77664954b7eb6d19b4469ade3d2
record_format Article
spelling doaj-8a4df77664954b7eb6d19b4469ade3d22020-11-25T03:53:41ZengPAGEPress PublicationsHematology Reports2038-83222038-83302009-07-0111e10e1010.4081/hr.2009.e10735The role of JAK2 abnormalities in hematologic neoplasms.Mohammed Khalid Alabdulaali0MOHIn 2005, an activating mutation in the Janus kinase 2 (JAK2) was identified in a significant proportion of patients with myeloproliferative neoplasms, mainly polycythemia vera, essential thrombocythemia and primary myelofibrosis. Many types of mutations in the JAK-STAT pathway have been identified, the majority are related to JAK2. Currently JAK2 mutations are important in the area of diagnosis of myeloid neoplasms, but its role beyond the confirmation of clonality is growing and widening our knowledge about these disorders. In addition to that, clinical trials to target JAK2-STAT pathway will widen our knowledge and hopefully will offer more therapeutic options. In this review, we will discuss the role of JAK2 abnormalities in the pathogenesis, diagnosis, classification, severity and management of hematologic neoplasms.http://www.pagepress.org/journals/index.php/hr/article/view/176JAK2Myeloproliferative neoplasmsLeukaemia
collection DOAJ
language English
format Article
sources DOAJ
author Mohammed Khalid Alabdulaali
spellingShingle Mohammed Khalid Alabdulaali
The role of JAK2 abnormalities in hematologic neoplasms.
Hematology Reports
JAK2
Myeloproliferative neoplasms
Leukaemia
author_facet Mohammed Khalid Alabdulaali
author_sort Mohammed Khalid Alabdulaali
title The role of JAK2 abnormalities in hematologic neoplasms.
title_short The role of JAK2 abnormalities in hematologic neoplasms.
title_full The role of JAK2 abnormalities in hematologic neoplasms.
title_fullStr The role of JAK2 abnormalities in hematologic neoplasms.
title_full_unstemmed The role of JAK2 abnormalities in hematologic neoplasms.
title_sort role of jak2 abnormalities in hematologic neoplasms.
publisher PAGEPress Publications
series Hematology Reports
issn 2038-8322
2038-8330
publishDate 2009-07-01
description In 2005, an activating mutation in the Janus kinase 2 (JAK2) was identified in a significant proportion of patients with myeloproliferative neoplasms, mainly polycythemia vera, essential thrombocythemia and primary myelofibrosis. Many types of mutations in the JAK-STAT pathway have been identified, the majority are related to JAK2. Currently JAK2 mutations are important in the area of diagnosis of myeloid neoplasms, but its role beyond the confirmation of clonality is growing and widening our knowledge about these disorders. In addition to that, clinical trials to target JAK2-STAT pathway will widen our knowledge and hopefully will offer more therapeutic options. In this review, we will discuss the role of JAK2 abnormalities in the pathogenesis, diagnosis, classification, severity and management of hematologic neoplasms.
topic JAK2
Myeloproliferative neoplasms
Leukaemia
url http://www.pagepress.org/journals/index.php/hr/article/view/176
work_keys_str_mv AT mohammedkhalidalabdulaali theroleofjak2abnormalitiesinhematologicneoplasms
AT mohammedkhalidalabdulaali roleofjak2abnormalitiesinhematologicneoplasms
_version_ 1724477379238166528